Cathie Wood Weighs In On Invitae Corp

Loading...
Loading...

Speaking on CNBC's "Closing Bell," Ark VInestment Management CEO Cathie Wood said Invitae Corp NVTA, in the molecular diagnostics space, is probably one of the most important companies in the genomic revolution and it's getting hammered.

Historically, Wood said, it has had small cash cushions although it rectified that with offerings, which is great. She added that the company is investing aggressively to be the leader in the molecular diagnostic and testing space.

See Also: Cathie Wood Shares Thoughts On Nano Dimension

Wood said the disconnect for many people here is when they think about lab tests, they think of Laboratory Corp. of America Holdings LH and Quest Diagnostics Inc DGX, which are effectively very mature companies, commoditized, value stocks. She expects the new lab tests to be supported by artificial intelligence, big data and supercomputing power amid a move towards personalized medicine, which is going to give just a few companies the lion share of the market.

These companies are going to have the most data, the highest quality data and the best AI expertise, Wood said.

Market News and Data brought to you by Benzinga APIs
Posted In: Health CareMediaTrading IdeasGeneralARK InvestCathie WoodClosing BellCNBC
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...